We report that type I interferons (IFNs) upregulate latent membrane protein 1 (LMP-1) expression by direct activation of the ED-L1 promoter in several Epstein-Barr virus (EBV)-carrying Burkitt's lymphoma lines. In EBV-infected primary B cells, IFN-␣ transiently upregulates LMP-1 mRNA, but not protein levels, followed by downregulation of both, suggesting a novel antiproliferative mechanism of type I IFNs. Furthermore, our results may explain the expression of LMP-1 in memory B cells of systemic lupus erythematosus patients.
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E
pstein-Barr virus (EBV) is a ubiquitous gammaherpesvirus associated with a wide variety of neoplasms, including Burkitt's lymphoma (BL), nasopharyngeal carcinoma, posttransplant lymphoproliferative disease, and Hodgkin's disease. Only a subset of viral genes is transcribed from latent episomal EBV genomes in lymphoblastoid cell lines (LCLs) and in EBV-associated neoplasms. Besides EBV-encoded RNAs (EBERs) and BamHI-A transcripts, in type I latency only EBV nuclear antigen 1 (EBNA-1) is expressed, while in type III latency all six EBNAs and three EBVencoded latent membrane proteins (LMPs) are expressed. In type II latency, which is observed in Hodgkin T cell and NK cell lymphomas, in the lymphoid tissues of healthy virus carriers and infectious mononucleosis patients one or all of the LMPs are expressed in addition to the type I latency gene products (39) . LMP-1 plays a central role in EBV biology, since it acts in part as a constitutively active CD40 receptor analog and is essential for B cell proliferation and transformation by EBV (24) . In type III latency, EBNA-2 is the major transactivator of the LMP promoters, while in type II latency, depending on the cellular context, different cytokines (interleukin-4 [IL-4], IL-10, -13, -15, and -21) are responsible for the activation of LMP-1 transcription (20, 26, 27, 28) .
Type I interferons (IFNs) are produced in relatively large amounts in response to pathogen sensing by the innate immune system (46) . In addition to their direct antiviral activities, these proteins also have antiproliferative and immunomodulatory properties. Consequently, type I IFNs find diverse clinical application in the treatment of certain forms of cancer, as well as in the therapy of viral infections or immunological disorders (31) . On the other hand, type I IFNs have a major pathophysiological role in human diseases, such as systemic lupus erythematosus (SLE), with characteristic high IFN-␣ levels (46) . Several interactions have been described between EBV and the type I IFN system. EBV virions and/or EBER1 (secreted in complex with lupus erythematosus-associated antigen or added exogenously in an in vitro-synthesized form) induces type I IFN production in several cell types, including B cells and plasmacytoid dendritic cells (21, 25, 38) . Conversely, IFN-␣ treatment of adult B cells prior to or at the time of in vitro infection nearly completely prevents EBV-mediated B cell proliferation and outgrowth into LCLs (30, 47) , at least partially through the inhibition of the capping of EBV-CD21 complexes (6) . However, EBV-infected B cells become progressively resistant to the effects of type I IFNs within a few days postinfection (30, 47) , possibly through the inhibitory effect of LMP-1 on IFN-␣-induced Tyk2 and subsequent STAT2 phosphorylation (12) . On the other hand, the mechanism of the partial inhibition of B cell transformation by type I IFNs added within the first 48 h after infection (30, 47) is still unidentified. Furthermore, despite the observation of this complex network of interactions, no direct effect of type I IFNs has been shown on the regulation of latent EBV gene expression. Using EBV-positive BL lines and freshly infected peripheral blood B cells, we show now that type I IFNs can directly modulate LMP-1 expression.
For initial experiments, we chose the highly IFN-␣-sensitive, EBV-positive BL line Daudi (29) , in which IFN-␣ treatment inhibits cell proliferation and concomitantly induces plasmacytoid differentiation (8) . Daudi cells were treated with different concentrations of IFN-␣, IFN-␤, and IFN-␥ (Peprotech) for 24 h, and the level of LMP-1 protein was analyzed by Western blotting (Fig.  1A) . Type I IFNs strongly upregulated LMP-1 protein expression in a dose-dependent manner, while IFN-␥ did not. Since the antiproliferative effect of IFN-␣ already reaches its maximum at 0.3 ng/ml (data not shown), while LMP-1 expression is not induced even at 0.5 ng/ml (Fig. 1A) , the growth-inhibitory effect of IFN-␣ on Daudi cells is not a consequence of LMP-1 upregulation.
Next, we analyzed the LMP-1-inducing effect of IFN-␣ on a panel of EBV-positive BL lines, including Daudi, Salina, and P3HR1 (lines carrying a virus strain that has a deletion involving EBNA-2, and therefore the cells use the W-promoter for the transcription of the EBNAs and do not express or express only mini- Table 1 , and PCR conditions are described in the text. CBM1, CBM1-Ral-STO cells.
mal amounts of LMPs [1, 4, 22, 23] ), the type I BL lines Akata (45), Rael (32) , and Jijoye-M13 (27) , the type III BL line Raji (28) , and the cord blood-derived LCL CBM1-Ral-STO, transformed with the Rael EBV strain (7). IFN-␣ treatment for 24 h led to the upregulation of LMP-1 protein expression in Jijoye-M13 cells and in all the BL lines carrying EBNA-2-deleted virus, while LMP-1 mRNA and protein levels did not increase in the other cell lines ( To analyze the kinetics and specificity of LMP-1 upregulation, LMP-1 mRNA and protein levels were measured together with LMP-2A and ISG56 mRNA expression in Daudi cells treated with IFN-␣ for 1, 3, 6, and 24 h (Fig. 1C) . Strong (50-fold) upregulation of LMP-1 mRNA was detected already after 1 h, with a maximum increase of more than 200-fold after 3 h, and then progressively decreased at 6 and 24 h. In contrast, LMP-2A mRNA was only slightly (2.1-fold) upregulated during the kinetic analysis, while ISG56 mRNA was rapidly and progressively upregulated to a maximum of 729-fold after 24 h. Upregulation of LMP-1 protein was detected already after 1 h, with a maximum after 6 h and a lower level after 24 h. These results show that IFN-␣ rapidly and specifically upregulates LMP-1 through transcriptional activation and with a kinetics different from the IFN-␣-induced upregulation of the classical target ISG56.
To analyze the role of the ED-L1 (2.8-kb mRNA [18] ) and L1-TR (3.5-kb mRNA [40] ) promoters in the IFN-␣-induced upregulation of LMP-1, the relative levels of total (2.8-and 3.5-kb mRNAs) and 3.5-kb LMP-1 mRNA were measured with real-time reverse transcription-PCR (RT-PCR) in Daudi cells left untreated or treated with IFN-␣ for 3 h (Fig. 1D) . The primers used for PCR analysis are listed in Table 1 To test whether de novo protein synthesis is required for the rapid induction of LMP-1 by type I IFNs, Daudi cells were preincubated with or without cycloheximide (CHX; Sigma-Aldrich), a protein synthesis inhibitor, for 30 min, after which the cells were left untreated or treated with IFN-␣ for an additional 1 h, and LMP-1 mRNA levels were measured (Fig. 1E) . CHX treatment did not block IFN-␣-induced upregulation of LMP-1 but strongly enhanced it, proving that LMP-1 transcription is directly induced by type I IFN signaling.
Type I IFNs activate the classical JAK/STAT and several alternate pathways, including the extracellular signal-regulated kinase 1 and 2 (ERK-1/2), p38 mitogen-activated protein kinase (MAPK), insulin receptor substrate (IRS)-phosphatidylinositol (PI) 3=-kinase, Jun N-terminal kinase (JNK), Crk, protein kinase C (PKC), and NF-B pathways (31, 35, 36, 37, 43) . First, we analyzed the role of the alternate pathways by measuring LMP-1 and ISG56 mRNA levels in Daudi cells treated with IFN-␣ or left untreated for 90 min in the presence or absence of inhibitors of MEK1 (PD98059; Calbiochem), p38 MAPK (SB203580; Calbiochem), PI 3=-kinase (wortmannin; Calbiochem), JNK-1, -2, and -3 (SP600125; Calbiochem), PKC␣, -␤, -␥, -␦, and -(Gö6850; Calbiochem), NF-B (BAY117082 [Calbiochem] and MG132 [Enzo]) ( Fig. 2A) . PD98059 did not, while all other inhibitors slightly (SB203580, wortmannin, SP600125, Gö6850, and MG132) or moderately (BAY117082) prevented LMP-1 upregulation. SB203580, wortmannin, and MG132 minimally inhibited, while all other inhibitors did not affect or slightly enhanced ISG56 upregulation. These results suggest a partial role for the NF-B, PKC, and JNK pathways in the type I IFN-induced transcription of LMP-1.
IFN-␣ activates STAT-1, -2, -3, -5, and -6 in human BL lines, mostly through the classical JAK/STAT pathway (9, 14, 43) . The tyrosine kinase inhibitor piceatannol has been reported to selectively prevent the IFN-␣-induced tyrosine phosphorylation of STAT-3 and -5, but not that of STAT-1 and -2 through the specific inhibition of Tyk2 kinase activity in the Ramos BL and Jurkat T cell lines (43) . Our analysis using Daudi cells showed that piceatannol (Sigma-Aldrich) strongly inhib- Total LMP-1  5=-GCAGGAGGGTGATCATCAGT-3=  5=-GTCCTCTATTCCTTTGCTCTCATG-3=  3.5-kb LMP-1  5=-TACGTAGCCGCCCTACATAAG-3=  5=-CCTCTCAAGGTCCAGGTCCAT-3=  LMP-2A  5=-CAGGCAGGCATACTGGATTC-3=  5=-CGATGAGGAACGTGAATCTAATG-3=  EBNA-2  5=-GGACACAAGAGCCATCACCT-3=  5=-CAAAGCATTCGCATAGCAGA-3=  ISG56 5=-GTGACATCTCAATTGCTCCAGAC-3= 5=-GGAGCCTGGCTAAGCAAAAC-3= GAPDH 5=-GGAAGGTGAAGGTCGGAGTCA-3= 5=-ATGGGTGGAATCATATTGGAACA-3=
a Sequences of forward and reverse primers are provided. The LMP-1 coding and regulatory regions containing the primer binding sites were sequenced in Daudi cells. Primers (Sigma-Aldrich) for LMP-1 were designed on the basis of these sequences.
its phosphorylation of STAT-5, while it only slightly prevents STAT-2 and -3 phosphorylation and does not affect STAT-1 phosphorylation upon IFN-␣ treatment (Fig. 2B) , providing an efficient tool for the selective analysis of the role of STAT-5 in the IFN-␣-induced upregulation of LMP-1. Since piceatannol is a specific inhibitor of Syk tyrosine kinase as well, the effect of BAY613606, a highly selective inhibitor of Syk (49), was also tested. Daudi cells were treated with IFN-␣ or left untreated for 90 min in the presence or absence of piceatannol or BAY613606 (Sigma-Aldrich), and LMP-1 and ISG56 mRNA levels were measured ( Fig. 2A) . Piceatannol strongly inhibited while BAY613606 moderately inhibited LMP-1 upregulation, although both compounds only slightly blocked ISG56 upregulation. These results suggest that STAT-1, -2, and -3 tyrosine phosphorylation is not needed or is not sufficient for the direct upregulation of LMP-1 mRNA by IFN-␣, while Tyk2 and Syk (Fig. 3A) , IFN-␣ treatment upregulated LMP-1 mRNA levels by 8-and 1.8-fold at the 8-and 30-h time points, respectively. In B cells of donor 2 at the 8-h time point (Fig. 3B) , LMP-1 mRNA could be detected only after IFN-␣ treatment, while EBNA-2 mRNA levels were nearly equal in both the untreated and treated samples. To analyze LMP-1 upregulation at the protein level, peripheral blood B cells were treated 24 h after EBV infection with IFN-␣ for 3 h (donor 3) or 24 h (donor 4), when LMP-1 mRNA and protein levels, together with the EBNA-2 protein level (only after the 24-h treatment), were measured (Fig. 3C) . Three hours of IFN-␣ treatment upregulated LMP-1 mRNA expression by 1.43-fold, while the LMP-1 protein level did not change, suggesting inhibition of LMP-1 translation. Interestingly, 24 h of IFN-␣ treatment moderately reduced (by 46%) LMP-1 mRNA, while it strongly downregulated LMP-1 (by 80%) and EBNA-2 protein levels. Since these proteins play an essential role in EBV-induced B cell transformation (24) , their downregulation may explain the previously reported partial inhibition of transformation by IFN-␣ when added 24 h postinfection (30, 47) . Previous publications also reported the downregulation of EBNAs upon type I IFN treatment in EBV-infected peripheral blood lymphocytes (17) , T cell-depleted mononuclear cells (5, 11) , and B cells (2) . However, in those studies, type I IFNs were added prior to or at the time of in vitro infection, when inhibition of EBV-mediated CD21 capping by IFN-␣ (6) may completely prevent later steps of the infection. Since viral entry and the transition to the circular form have already occurred by 24 h postinfection (19) , inhibition of these steps cannot be responsible for the observed downregulation of EBNA-2 and LMP-1 in our experiments, suggesting a novel inhibitory mechanism of type I IFNs on EBV-induced B cell transformation. According to previous publications (2=-5=), oligoadenylates may play a role in this mechanism (17) .
SLE is a complex, multifactorial disease involving genetic, epigenetic, and environmental risk factors, but it is now well-established that elevated levels of type I IFNs have a central role in its pathophysiology (46) . Several lines of evidence suggest that EBV infection also plays an important role in the pathophysiology of SLE, possibly by antigenic cross-reactivity between viral antigens and self-antigens, and/or the rescue of preexisting autoreactive B cells from apoptosis (15, 34) . LMP-1 mRNA is the most frequently detected latent EBV product in the increased population of EBVinfected memory B cells in the blood of SLE patients, although it is never detected in the blood of healthy individuals (13) . Since LMP-1 induces B cells to express B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL), which are mediators of B cell survival, T cell-independent antibody production, and immunoglobulin class switching (16), LMP-1 appears to be an important link between EBV infection and SLE. Since EBV-positive BLs originate from and therefore represent either late germinal center B cells or memory B cells (3, 48) , our observations on the LMP-1-inducing effect of IFN-␣ in these lines and in primary B cells may explain the expression of LMP-1 mRNA in the memory B cells of SLE patients and suggest a direct connection between immune dysfunction and altered regulation of EBV latency in SLE. However, the lack of IFN-␣-induced LMP-1 protein upregulation, despite its transcriptional induction in primary B cells, calls for careful analysis of LMP-1 protein expression in the memory B cells of SLE patients in future studies.
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